Therapeutics for Triple Negative Breast Cancer
Researchers at Purdue University have developed a new technology that could change how breast cancer is treated. The researchers have developed new drug candidates that are potent at lower concentrations than chemotherapy. The technology employs molecules that are selectively taken up by cancer cells and activated by light. In vitro, this therapeutic drug is photoactive at the nanomolar range with an appropriate light dose adjustment and has no observable toxicity when not exposed to light. This targeted therapy promises to reduce the dosage of drug needed to treat TNBC and effectively reduce side effects.
Reduced adverse effectsTargeted therapy Potent at low concentrations
Breast cancer Cancer therapeutics
Meden F. Isaac-LamPurdue Northwest Biological Sciences
United States
None
美國
